Experienced in Fibrosarcoma

Dr. Mildred R. Ridgway

Gynecologic Oncology | Oncology | Obstetrics and Gynecology
State Of Mississippi - University Of Mississippi Medical Center
2500 N State St, 
Jackson, MS 
Accepting New Patients
Offers Telehealth
Experienced in Fibrosarcoma
State Of Mississippi - University Of Mississippi Medical Center
2500 N State St, 
Jackson, MS 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mildred Ridgway is a Gynecologic Oncologist and an Oncologist in Jackson, Mississippi. Dr. Ridgway is rated as an Experienced provider by MediFind in the treatment of Fibrosarcoma. Her top areas of expertise are Cervical Cancer, Neuroendocrine Carcinoma of the Cervix, Vulvar Cancer, Reconstructive Urology Surgery, and Salpingo-Oophorectomy. Dr. Ridgway is currently accepting new patients.

Her clinical research consists of co-authoring 13 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in MS
Hospital Affiliations
University Of Mississippi Med Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Magnolia Health
  • HMO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

STATE OF MISSISSIPPI - UNIVERSITY OF MISSISSIPPI MEDICAL CENTER
2500 N State St, Jackson, MS 39216

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 05, 2025
Intervention Type: Radiation, Drug, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 3
An Open-Label, Multi-Center Patient Access Program of Olaratumab for the Treatment of Soft Tissue Sarcoma
An Open-Label, Multi-Center Patient Access Program of Olaratumab for the Treatment of Soft Tissue Sarcoma
Enrollment Status: Approved_for_marketing
Publish Date: December 16, 2024
Intervention Type: Drug
Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (≤ 2CM) Cervical Cancer
Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (≤ 2CM) Cervical Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 03, 2024
Intervention Type: Other, Procedure
Study Phase: Not Applicable
View 4 Less Clinical Trials

13 Total Publications

Abruption of Abdominal Pregnancy Following Blunt Trauma.
Abruption of Abdominal Pregnancy Following Blunt Trauma.
Journal: The American surgeon
Published: May 19, 2023
Similar Doctors
Advanced in Fibrosarcoma
Dr. Tammy H. Young
Oncology | Hematology
Advanced in Fibrosarcoma
Dr. Tammy H. Young
Oncology | Hematology

Jackson Oncology Associates

1227 N State St, Suite 101, 
Jackson, MS 
 (1.2 miles away)
601-355-2485
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Tammy Young is an Oncologist and a Hematologist in Jackson, Mississippi. Dr. Young is rated as a Distinguished provider by MediFind in the treatment of Fibrosarcoma. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Pleuropulmonary Blastoma, Lung Cancer, and Advanced Bronchoscopy. Dr. Young is currently accepting new patients.

Advanced in Fibrosarcoma
Dr. Robert D. Hamilton
Oncology
Advanced in Fibrosarcoma
Dr. Robert D. Hamilton
Oncology
2500 North State Street, Department Of Medicine/division Of Hematology, 
Jackson, MS 
 (0.1 miles away)
601-984-5615
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Robert Hamilton is an Oncologist in Jackson, Mississippi. Dr. Hamilton is rated as an Advanced provider by MediFind in the treatment of Fibrosarcoma. His top areas of expertise are Neuroendocrine Tumor, Bone Tumor, Laryngeal Cancer, Endoscopy, and Pancreatectomy. Dr. Hamilton is currently accepting new patients.

Experienced in Fibrosarcoma
Dr. Donald P. Seago
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Experienced in Fibrosarcoma
Dr. Donald P. Seago
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

State Of Mississippi - University Of Mississippi Medical Center

2500 N State St, 
Jackson, MS 
 (0.1 miles away)
601-815-4775
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Donald Seago is a Gynecologic Oncologist and an Oncologist in Jackson, Mississippi. Dr. Seago is rated as a Distinguished provider by MediFind in the treatment of Fibrosarcoma. His top areas of expertise are Malignant Mixed Mullerian Tumor, Endometrial Cancer, Neuroendocrine Carcinoma of the Cervix, Hernia Surgery, and Bladder Reconstruction. Dr. Seago is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ridgway's expertise for a condition
ConditionClose
    View All 17 Distinguished Conditions
    View All 7 Advanced Conditions
    View All 28 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile